8,660.2518.8
Stock Analysis, IPO, Mutual Funds, Bonds & More

Daiichi-Ranbaxy arbitration case: Singh brothers hearing in Singapore Supreme Court starts today

A Singapore tribunal in 2016 awarded Daiichi Rs 3,500 crore in damages. In May that year, the company moved Delhi High Court to enforce the award. The Singhs appealed against it in Singapore as well as India.

, ET Bureau|
Last Updated: Feb 24, 2020, 07.55 AM IST
0Comments
1
Former Ranbaxy promoters Malvinder and Shivinder Singh
NEW DELHI: The Supreme Court of Singapore will, from Monday, hear a plea by former Ranbaxy promoters Malvinder and Shivinder Singh that challenges Japanese drug maker Daiichi Sankyo’s arbitration award.

A Singapore tribunal in 2016 awarded Daiichi Rs 3,500 crore in damages. In May that year, the company moved Delhi High Court to enforce the award. The Singhs appealed against it in Singapore as well as India.

“The final hearing will begin tomorrow in the Supreme Court of Singapore. Senior counsels of Malvinder and Shivinder Singh in Singapore will appear,” a person in the know told ET.

Senior advocate Harish Salve in 2017 filed an application to represent the Singh brothers. He sought an exemption from a Singapore law that generally bars foreign lawyers from appearing in local courts.

However, he was denied by the Singapore court.

Among other things, the court said no questions of Indian law were involved at that stage. Even at an earlier stage, when issues related to Indian law had arisen, the sellers had employed senior counsel from Singapore, the court noted, and only filed evidence from Indian law experts to defend their cases.

Delhi High Court in January 2018 ruled in favour of Daiichi.

Also Read

Singapore Airlines to start fifth weekly flight on Kolkata-Singapore route

Techchefs to expand to US, Singapore

Singapore to shut bars, cinemas to tackle Covid-19

Singapore Airlines obtains $13 billion rescue package amid coronavirus shock

Singapore reports two deaths from coronavirus, first fatalities in country

Comments
Add Your Comments
Commenting feature is disabled in your country/region.

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service